Trials / Terminated
TerminatedNCT05384249
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- ACELYRIN Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Izokibep | Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC) |
| DRUG | Placebo | Form: Solution for injection Route of administration: Subcutaneous (SC) |
Timeline
- Start date
- 2022-08-23
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
- First posted
- 2022-05-20
- Last updated
- 2025-02-21
Locations
69 sites across 7 countries: United States, Austria, Czechia, France, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05384249. Inclusion in this directory is not an endorsement.